Company Performance Metrics
- David Ribeiro: Chief Executive Officer
- Sarah Johnston: Scientist
ProAxsis Ltd. specialises in the development of laboratory-based immunoassays and rapid point-of-care tests for the capture, detection and measurement of active protease biomarkers of disease.
Its rapid and easy-to-use tests incorporate patented “ProteaseTags®”; smart molecules which trap an active protease within a complex biological sample and
enable a visual readout of its presence. A number of active protease species have been extensively validated as biomarkers of disease activity in areas such as cancer and infection, in addition to respiratory diseases such as bronchiectasis, cystic fibrosis and COPD.
Its first immunoassay, for the specific measurement of active neutrophil elastase as a biomarker of lung infection and inflammation, was registered with a European CE Mark in 2016.
